Goldman Sachs Group Inc Procept Bio Robotics Corp Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 275,869 shares of PRCT stock, worth $8.19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
275,869
Previous 350,520
21.3%
Holding current value
$8.19 Million
Previous $20.2 Million
51.24%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding PRCT
# of Institutions
272Shares Held
49.1MCall Options Held
274KPut Options Held
376K-
Vanguard Group Inc Valley Forge, PA5.21MShares$155 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$103 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY3.42MShares$102 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.05MShares$60.9 Million0.04% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.97MShares$58.5 Million0.32% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $1.32B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...